CurrentCareSourcePolicy N/A

Antiemetics - Palonosetron Intravenous Products Utilization Management Medical Policy

Defines prior authorization and coverage criteria for palonosetron intravenous products for prevention of chemotherapy-induced and postoperative nausea and vomiting for CareSource members.

Policy Summary

PayerCareSource

PolicyAntiemetics - Palonosetron Intravenous Products Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeAdded branded productdosing revised

Effective Date

Next Review DateMay 7, 2025

Key ActionObtain prior authorization for palonosetron IV; EviCore-managed reviews may be required for oncology indications.

SourceLink

POLICY UPDATE CHANGES

Posfrea (palonosetron intravenous infusion) was added to the Policy.

Title updated from 'Antiemetics - Palonosetron Intravenous' to 'Antiemetics - Palonosetron Intravenous Products'.

Adult dosing for chemotherapy-induced nausea and vomiting updated to allow up to two doses per cycle.

2FDA-approved indication categories (CINV, PONV)

0.25 mgmax adult IV dose per administration (CINV)

20 mcg/kgpediatric single-dose IV (CINV)

0.075 mgadult IV dose (PONV)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1 yrauthorization period (CINV)

Recommended Authorization & Coverage Criteria

Recommended Authorization Criteria

Coverage of palonosetron IV is recommended in those who meet one of the following criteria:

FDA-Approved Indications

Chemotherapy-Induced Nausea and Vomiting, Prevention (CINV): Patient receiving chemotherapy (initial or repeat courses) and request is for prevention of acute and/or delayed CINV
[EviCore] Approve for 1 year. Dosing: Adults — approve up to 0.25 mg IV, up to two doses per chemotherapy cycle; Pediatrics (<18 years) — approve up to 20 mcg/kg IV (max 1.5 mg), one dose per cycle.
Postoperative Nausea and Vomiting, Prevention (PONV): Patient is ≥ 18 years and request is for prevention of PONV
Approve for one dose. Dosing: approve up to 0.075 mg IV for one dose.

ref frittered_by_user_request_but_must_match_exactly_b0_0_xxx___do_not_change_ref__PLEASE_FIX_IF_VALIDATION_requires_replacement_b0_0___REPLACE_WITH_EXACT_REF_PROVIDED_IN_PROMPT___b0_0___THIS_LINE_MUST_BE_REMOVED_AND_REF_FIELD_PRESENT_ALONE_IN_OBJECT

Coverage of palonosetron IV for radiation-induced nausea and vomiting is not recommended. Clinical guidance from NCCN (v1.2025) and ASCO (2020) identify ondansetron and granisetron as the preferred 5-HT3 receptor antagonists and note insufficient evidence to support use of palonosetron IV in this setting.

Requests for palonosetron IV for indications or circumstances that are not listed in the Recommended Authorization Criteria are not recommended for coverage. The policy indicates that criteria will be updated as new published data become available.

Use of palonosetron IV specifically for radiation-induced nausea and vomiting is not supported by the evidence cited in guideline reviews and therefore is not recommended for approval. For patients receiving both chemotherapy and radiation, the chemotherapy-related indication should be evaluated under the FDA‑approved CINV criteria.

Guideline-Recommended Antiemetic Regimens

Regimen	Dosing / Age	Coverage Status
Palonosetron IV as part of guideline-recommended antiemetic combination regimens for prevention of acute and delayed chemotherapy‑induced nausea and vomiting (CINV).
Adults: 0.25 mg IV; approve up to two doses per chemotherapy cycle.
Covered when used per criteria (FDA‑approved CINV indication and guideline‑recommended combination regimens).
Pediatrics (<18 years): 20 mcg/kg IV (maximum 1.5 mg) as a single dose per chemotherapy cycle; use in selected pediatric patients per ASPHO guidance.
Use consistent with NCCN/ASCO/ASPHO guideline recommendations for combination antiemetic regimens.

Dosing, Repeat Interval, and Coding Notes

Repeat dosing interval — evidence and guidance

Repeat dosing intervalRepeat dosing 48 to 72 hours after chemotherapy appears to be safe and effective.

ContextGuideline note from NCCN antiemesis guidance (version 1.2025).

ApplicationApplies to palonosetron IV dosing in the prevention of chemotherapy‑induced nausea and vomiting (CINV).

Authorization, Routing, and Denial Guidance for Providers

Prior Authorization

Prior Authorization Recommended

Prior authorization is recommended for medical benefit coverage of palonosetron IV. Approvals are granted for durations specified in the policy (for CINV: up to 1 year for EviCore-managed reviews; for PONV: one dose when patient is ≥ 18 years). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside established dosing will be considered case-by-case by a clinician. For oncology and oncology-related reviews managed by EviCore, prior authorization requests should be directed to EviCore at www.EviCore.com.

Approval durations: CINV — up to 1 year (EviCore-managed); PONV — one dose (≥ 18 years).
Dose exceptions require clinician review (Medical Director or Pharmacist).
EviCore-managed oncology reviews: prior authorization via www.EviCore.com.

Step Therapy

Step Therapy / Preferred Agents

No step therapy is specified in this policy. However, clinical guidelines and the policy reference preferred 5-HT3 agents (e.g., ondansetron, granisetron) for certain indications such as radiation-induced nausea and vomiting — where palonosetron IV is not recommended. Providers should consider guideline-preferred agents when appropriate prior to requesting palonosetron for non-listed indications.

Drug Class and Pharmacology

Palonosetron mechanism

Mechanism of actionPalonosetron is a 5‑HT3 (serotonin) receptor antagonist that blocks serotonin‑stimulated emetic responses.

Receptor affinityHas strong affinity for the 5‑HT3 receptor and little or no affinity for other receptors.

Clinical roleUsed to prevent acute and delayed chemotherapy‑induced and postoperative nausea and vomiting as part of guideline‑recommended antiemetic regimens.

Half‑life (approximate)

Approximate elimination half‑life~40 hours.

Clinical relevanceLong half‑life contributes to activity against both acute and delayed CINV and supports dosing intervals described in guidelines.

Clinical Background

Palonosetron is a 5-HT3 receptor antagonist with high affinity for the 5-HT3 receptor and minimal activity at other receptors. It has an extended elimination half-life of approximately 40 hours and is used as part of guideline-recommended antiemetic regimens to prevent both acute and delayed chemotherapy-induced nausea and vomiting (CINV) and to prevent postoperative nausea and vomiting (PONV).

Therapy Positioning

Line of Therapy — CINV setting

CINV setting: Prevention for acute and delayed CINV associated with initial and repeat courses of moderately or highly emetogenic chemotherapy in adults and selected pediatric patients

Includes repeat dosing up to two doses per cycle for adults; approval duration up to 1 year for EviCore-managed reviews.

Policy Updates and Change Log

2025-05-21brand_additionLatest

Posfrea (palonosetron intravenous infusion) was added to the policy and the title was updated to 'Antiemetics - Palonosetron Intravenous Products'.

2025-05-07dosing_update

Adult dosing for chemotherapy-induced nausea and vomiting was updated to allow up to two doses per chemotherapy cycle (previously limited to one dose).

2024-05-01

Policy Summary

PayerCareSource

PolicyAntiemetics - Palonosetron Intravenous Products Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeAdded branded productdosing revised

Effective Date

Next Review DateMay 7, 2025

Key ActionObtain prior authorization for palonosetron IV; EviCore-managed reviews may be required for oncology indications.

SourceLink

On This Page

No formal step-therapy program is defined in this policy.
Radiation-induced N/V: ondansetron or granisetron are guideline-preferred; palonosetron IV requests for this indication are not recommended for approval.

Documentation Required

Prior Authorization Routing and Documentation

Prior authorization routing and documentation: direct prior authorization review to EviCore for oncology and oncology-related indications noted with [EviCore]. Ensure documentation supports the FDA‑approved indication and dosing in the policy. Requests for indications not listed in the Recommended Authorization Criteria or for radiation‑induced N/V are not recommended for approval and may be denied.

Route oncology/oncology-related PA requests to EviCore at www.EviCore.com when indicated.
Include clinical documentation showing the patient meets the policy’s Criteria and Dosing (e.g., chemotherapy regimen, age, dosing).
Requests for unlisted indications or radiation-induced N/V may be denied.

Denial Risk

Radiation-Induced Nausea & Vomiting — Not Recommended

Requests for palonosetron IV for radiation-induced nausea and vomiting are not recommended for approval. NCCN and ASCO guidelines recommend ondansetron or granisetron for radiation-induced N/V and note insufficient evidence for palonosetron in this setting.

Radiation-induced N/V: palonosetron IV requests are not recommended for approval and may be denied.
If patient also receives chemotherapy, consider FDA‑approved CINV indication criteria.

Denial Risk

Unlisted Indications — Denial Risk

Coverage for indications not listed in the Recommended Authorization Criteria is not recommended and may be denied. The policy will be updated as new published data become available.

Unlisted indications: requests are not recommended for approval and may be denied.
Policy updates will reflect new evidence as available.

Source statementHalf‑life and dosing references cited in NCCN guidance and product dosing information.

Policy title was updated from 'Antiemetics - Aloxi Intravenous' to 'Antiemetics - Palonosetron Intravenous'.

2023-05-03annual_revision

Annual revision completed (no criteria changes documented in summary).